Citation Impact
Citing Papers
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
2015
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Colorectal cancer statistics, 2020
2020 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Breast cancer
2019 Standout
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Germline development from human pluripotent stem cells toward disease modeling of infertility
2012 StandoutNobel
QuPath: Open source software for digital pathology image analysis
2017 Standout
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis
2016
Biomarkers of response to PD-1/PD-L1 inhibition
2017
Establishing the Diagnosis of Lung Cancer
2013 Standout
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Hepatocellular carcinoma
2018 Standout
Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers
2016
Ovarian cancer
2014 Standout
Macrophage spatial heterogeneity in gastric cancer defined by multiplex immunohistochemistry
2019
BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy
2008
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Cancer drug resistance: an evolving paradigm
2013 Standout
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
2016 Standout
EMT Transition States during Tumor Progression and Metastasis
2018 Standout
Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer
2016
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
2019
Benefits and Challenges with Applying Unique Molecular Identifiers in Next Generation Sequencing to Detect Low Frequency Mutations
2016
Delivery technologies for cancer immunotherapy
2019 Standout
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
2014
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
A Human Monoclonal Antibody Targeting Scavenger Receptor Class B Type I Precludes Hepatitis C Virus Infection and Viral Spread In Vitro and In Vivo
2011 StandoutNobel
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2013
The long and winding road leading to the identification of the hepatitis C virus
2009 StandoutNobel
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
2008 StandoutNobel
The ins and outs of hepatitis C virus entry and assembly
2013 StandoutNobel
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
2019
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Male breast cancer: a disease distinct from female breast cancer
2018
Gastric cancer
2020 Standout
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial
2012
Treatment of Stage IV Non-small Cell Lung Cancer
2013
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Crizotinib in the Treatment of Non–Small-Cell Lung Cancer
2013
Recent progress in the diagnosis and treatment of ovarian cancer
2011
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression
2016 Standout
Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma
2016
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence
2018
Replication of hepatitis C virus
2007 StandoutNobel
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura
2010
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Broadly neutralizing antibodies abrogate established hepatitis C virus infection
2014 StandoutNobel
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis
2016
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
2012
RNA-dependent RNA targeting by CRISPR-Cas9
2018 StandoutNobel
Colorectal cancer statistics, 2017
2017 Standout
Seed Sequence-Matched Controls Reveal Limitations of Small Interfering RNA Knockdown in Functional and Structural Studies of Hepatitis C Virus NS5A-MOBKL1B Interaction
2014 StandoutNobel
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
2009 Standout
A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches
2018
The Mammalian Ovary from Genesis to Revelation
2009
Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells
2021 StandoutNobel
Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platform
2014
The synergistic cytotoxic effect of cisplatin and honey bee venom on human ovarian cancer cell line A2780cp.
2012
Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity
2009 StandoutNobel
Genetic and Functional Characterization of the N-Terminal Region of the Hepatitis C Virus NS2 Protein
2013 StandoutNobel
Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells
2013 StandoutNobel
Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission
2013 StandoutNobel
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis
2017
Works of Sérgio Rizzo being referenced
Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario
2014
Hereditary ovarian cancer
2008
Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?
2008
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
2010
Intercellular Communication and Human Hepatocellular Carcinoma
2004
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis
2015
A headlight on liquid biopsies: a challenging tool for breast cancer management
2016
Gemcitabine‐based doublets versus single‐agent therapy for elderly patients with advanced nonsmall cell lung cancer
2009
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
2010
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura‐hemolytic uremic syndrome: the role of rituximab
2010
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?
2016
Male breast cancer
2009
The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway
2009
PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
2016
Looking for the best immune‐checkpoint inhibitor in pre‐treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab
2017
Early Skin Toxicity as a Predictive Factor for Tumor Control in Hepatocellular Carcinoma Patients Treated with Sorafenib
2010
Monoclonal antibodies in gastrointestinal cancers
2013
The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients
2013